We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Invest in Align Technology (ALGN) Now
Read MoreHide Full Article
Align Technology, Inc. (ALGN - Free Report) has been gaining from substantial Invisalign portfolio expansion. The company is focusing on expanding the workflow options of its leading iTero scanners. The raised 2023 outlook buoys optimism about the stock.
In the past year, this Zacks Rank #1 (Strong Buy) stock has gained 36.9% compared with a 6% rise in the industry and a 11% rise in the S&P 500 composite.
The renowned global medical device company has a market capitalization of $26.81 billion. The company’s expected long-term earnings growth of 17.5%, ahead of the industry’s 12.3% rise.
Let’s delve deeper.
Key Growth Drivers
Invisalign Portfolio Expansion: Align Technology’s Invisalign portfolio offers orthodontic treatment to straighten teeth without metal braces.
In the second quarter of 2023, the company successfully rolled out the Invisalign Comprehensive Three and Three product in APAC, which is now available in Hong Kong, Korea, Taiwan, and India. It also has plans to launch Invisalign Three and Three products in China in the third quarter of 2023.
The company launched Invisalign Comprehensive three and three products in most markets earlier. Instead of unlimited additional aligners within five years of the treatment end date, the latest configuration offers Invisalign comprehensive treatment with three other aligners included within three years of the treatment end date.
iTero in Focus: Align Technology has been focusing on expanding the workflow options of its leading iTero scanners. Of late, company revenues have been positively impacted by higher subscription revenues from many iTero scanners in the field. The company also had higher non-systems revenues reflecting increased scanner rentals, upgrades and certified pre-owned or CPO leasing programs.
Recently, the company talked about iTero-exocad Connector, which integrates iTero intraoral camera and NIRI images with exocad DentalCAD 3.1 software and allows dental professionals to visualize the internal and external structure of teeth. According to the company, the use of iTero scanners for Invisalign case submissions continues to grow and remains a positive catalyst for Invisalign utilization.
Upbeat Guidance: ALGN anticipates revenues in the range of $3.97 billion-$3.99 billion for the full year, implying a 12% improvement from 2022 at the midpoint. The Zacks Consensus Estimate for Align Technology’s 2023 revenues is pegged at $3.89 billion.
Image Source: Zacks Investment Research
The company expects a 2023 GAAP operating margin of slightly more than 17% and an adjusted operating margin of slightly higher than 21%.
For 2023, Align Technology expects investments in capital expenditures to be approximately $200 million. Capital expenditures are primarily related to building construction and improvements and additional manufacturing capacity to support Align Technology’s international expansion.
Estimate Trend
In the past 90 days, the Zacks Consensus Estimate for Align Technology’s 2023 earnings has moved 5.3% north to $8.75.
The Zacks Consensus Estimate for the company’s 2023 revenues is pegged at $3.98 billion, suggesting a 6.5% surge from the year-ago reported number.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Elevance Health, Inc. (ELV - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Patterson Companies, Inc. (PDCO - Free Report) .
Elevance Health reported second-quarter 2023 adjusted EPS of $9.04, beating the Zacks Consensus Estimate by 2.5%. Revenues of $43.38 billion surpassed the Zacks Consensus Estimate by 4.5%. It currently carries a Zacks Rank #2 (Buy).
Elevance Health has a long-term estimated growth rate of 12.1%. ELV’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 2.8%.
Integer Holdings reported second-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 15.2%. Revenues of $400 million surpassed the Zacks Consensus Estimate by 8.9%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 12.1%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 8.4%.
Patterson Companies has an Earnings ESP of +5.66% and a Zacks Rank of 1. PDCO has an estimated long-term growth rate of 9.2%.
Patterson Companies’ earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 4.5%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Here's Why You Should Invest in Align Technology (ALGN) Now
Align Technology, Inc. (ALGN - Free Report) has been gaining from substantial Invisalign portfolio expansion. The company is focusing on expanding the workflow options of its leading iTero scanners. The raised 2023 outlook buoys optimism about the stock.
In the past year, this Zacks Rank #1 (Strong Buy) stock has gained 36.9% compared with a 6% rise in the industry and a 11% rise in the S&P 500 composite.
The renowned global medical device company has a market capitalization of $26.81 billion. The company’s expected long-term earnings growth of 17.5%, ahead of the industry’s 12.3% rise.
Let’s delve deeper.
Key Growth Drivers
Invisalign Portfolio Expansion: Align Technology’s Invisalign portfolio offers orthodontic treatment to straighten teeth without metal braces.
In the second quarter of 2023, the company successfully rolled out the Invisalign Comprehensive Three and Three product in APAC, which is now available in Hong Kong, Korea, Taiwan, and India. It also has plans to launch Invisalign Three and Three products in China in the third quarter of 2023.
The company launched Invisalign Comprehensive three and three products in most markets earlier. Instead of unlimited additional aligners within five years of the treatment end date, the latest configuration offers Invisalign comprehensive treatment with three other aligners included within three years of the treatment end date.
iTero in Focus: Align Technology has been focusing on expanding the workflow options of its leading iTero scanners. Of late, company revenues have been positively impacted by higher subscription revenues from many iTero scanners in the field. The company also had higher non-systems revenues reflecting increased scanner rentals, upgrades and certified pre-owned or CPO leasing programs.
Recently, the company talked about iTero-exocad Connector, which integrates iTero intraoral camera and NIRI images with exocad DentalCAD 3.1 software and allows dental professionals to visualize the internal and external structure of teeth. According to the company, the use of iTero scanners for Invisalign case submissions continues to grow and remains a positive catalyst for Invisalign utilization.
Upbeat Guidance: ALGN anticipates revenues in the range of $3.97 billion-$3.99 billion for the full year, implying a 12% improvement from 2022 at the midpoint. The Zacks Consensus Estimate for Align Technology’s 2023 revenues is pegged at $3.89 billion.
Image Source: Zacks Investment Research
The company expects a 2023 GAAP operating margin of slightly more than 17% and an adjusted operating margin of slightly higher than 21%.
For 2023, Align Technology expects investments in capital expenditures to be approximately $200 million. Capital expenditures are primarily related to building construction and improvements and additional manufacturing capacity to support Align Technology’s international expansion.
Estimate Trend
In the past 90 days, the Zacks Consensus Estimate for Align Technology’s 2023 earnings has moved 5.3% north to $8.75.
The Zacks Consensus Estimate for the company’s 2023 revenues is pegged at $3.98 billion, suggesting a 6.5% surge from the year-ago reported number.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Elevance Health, Inc. (ELV - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Patterson Companies, Inc. (PDCO - Free Report) .
Elevance Health reported second-quarter 2023 adjusted EPS of $9.04, beating the Zacks Consensus Estimate by 2.5%. Revenues of $43.38 billion surpassed the Zacks Consensus Estimate by 4.5%. It currently carries a Zacks Rank #2 (Buy).
You can see the complete list of today’s Zacks #1 Rank stocks here.
Elevance Health has a long-term estimated growth rate of 12.1%. ELV’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 2.8%.
Integer Holdings reported second-quarter 2023 adjusted EPS of $1.14, beating the Zacks Consensus Estimate by 15.2%. Revenues of $400 million surpassed the Zacks Consensus Estimate by 8.9%. It currently carries a Zacks Rank #2.
Integer Holdings has a long-term estimated growth rate of 12.1%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 8.4%.
Patterson Companies has an Earnings ESP of +5.66% and a Zacks Rank of 1. PDCO has an estimated long-term growth rate of 9.2%.
Patterson Companies’ earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 4.5%.